Define biotransformation and discuss the pathways of biotransformation of drugs in animal body.

Biotransformation, also known as drug metabolism, is the process by which the body chemically modifies a drug. It is a critical determinant of drug efficacy, duration of action, and potential toxicity. The process primarily occurs in the liver, but also in other tissues like the kidneys, intestines, and lungs. Understanding biotransformation is fundamental for veterinarians to optimize drug dosage, predict drug interactions, and minimize adverse effects in animals. The complexity arises from the diverse enzymatic reactions involved, which can either activate or inactivate a drug. Recent advances in pharmacogenomics are increasingly revealing individual variations in biotransformation capabilities, impacting treatment outcomes. Defining Biotransformation Biotransformation is the enzymatic alteration of a drug within the body. It’s a two-phase process designed to convert lipophilic drugs into more hydrophilic metabolites, facilitating their excretion from the body. Phase I reactions typically involve oxidation, reduction, or hydrolysis, while Phase II reactions involve conjugation, where a polar molecule is added to the drug or its Phase I metabolite. Phase I Reactions: Functionalization Phase I reactions introduce or expose a functional group (e.g., -OH, -NH2, -SH) on the drug molecule. This makes the drug more polar, but not always sufficiently so for excretion. The cytochrome P450 (CYP) enzyme system is the most important group of enzymes involved in Phase I. Oxidation: The most common Phase I reaction, catalyzed by CYP enzymes. Examples include: S-oxidation: Metabolism of thioethers. N-oxidation: Metabolism of amines. Hydroxylation: Addition of -OH groups, common in steroids. Reduction: Less common than oxidation. Involves the addition of electrons. Important in the metabolism of nitro compounds and some steroids. Hydrolysis: Involves the addition of water to break ester or amide bonds. Examples include the metabolism of aspirin and procaine. Phase II Reactions: Conjugation Phase II reactions involve the conjugation of a drug or its Phase I metabolite with a polar molecule, making it significantly more water-soluble and readily excretable. These reactions are generally catalyzed by transferase enzymes. Glucuronidation: The most common Phase II reaction. UDP-glucuronosyltransferases (UGTs) catalyze the addition of glucuronic acid to drugs and metabolites. Sulfation: Sulfotransferases (SULTs) catalyze the addition of sulfate groups. Acetylation: N-acetyltransferases (NATs) catalyze the addition of acetyl groups. Glutathione Conjugation: Glutathione S-transferases (GSTs) catalyze the conjugation of glutathione to electrophilic drugs or metabolites. This is an important detoxification pathway. Amino Acid Conjugation: Conjugation with amino acids like glycine or taurine. Table: Summary of Biotransformation Pathways Phase Reaction Type Enzymes Involved Outcome Phase I Oxidation Cytochrome P450 (CYP) enzymes Introduction or exposure of a functional group Phase I Reduction Various reductases Addition of electrons Phase I Hydrolysis Esterases, Amidases Cleavage of ester or amide bonds Phase II Glucuronidation UDP-glucuronosyltransferases (UGTs) Addition of glucuronic acid Phase II Sulfation Sulfotransferases (SULTs) Addition of sulfate Factors Affecting Biotransformation Several factors can influence the rate and extent of drug biotransformation: Species Differences: Significant variations exist in enzyme activity and expression across different animal species. Age: Neonates and geriatric animals often have reduced metabolic capacity. Disease State: Liver disease significantly impairs biotransformation. Drug Interactions: Enzyme induction (increased enzyme activity) or inhibition (decreased enzyme activity) by other drugs can alter drug metabolism. Genetics: Genetic polymorphisms in drug-metabolizing enzymes can lead to variability in drug response. CYP2D6 Polymorphisms in Dogs The CYP2D6 enzyme is crucial in the metabolism of several drugs in dogs. Genetic variations (polymorphisms) in the CYP2D6 gene can result in "poor metabolizers" (reduced enzyme activity) or "ultra-rapid metabolizers" (increased enzyme activity), significantly impacting drug efficacy and risk of toxicity. This is particularly relevant for drugs like codeine, which is metabolized by CYP2D6 to morphine. What is the difference between enzyme induction and inhibition? Enzyme induction increases the synthesis of metabolizing enzymes (like CYP450s), leading to faster drug metabolism. Enzyme inhibition decreases enzyme activity, slowing down drug metabolism. Veterinary Pharmaceutical Inspection and Enforcement This scheme, overseen by various national regulatory bodies, ensures that pharmaceutical manufacturers adhere to good manufacturing practices (GMP) and quality control standards, indirectly impacting the consistency of drug metabolism studies and ensuring accurate labeling regarding potential drug interactions. Ongoing Ivermectin Resistance in Parasites Repeated exposure to ivermectin, an antiparasitic drug, has led to the development of resistance in some parasite populations. This resistance often arises due to mutations in parasite genes that alter the drug's target site. However, altered drug metabolism in the host animal (e.g., increased CYP activity leading to faster ivermectin clearance) can also contribute to treatment failure, highlighting the interplay between parasite and host metabolism. Understanding the role of host metabolism in drug resistance is crucial for developing strategies to overcome resistance and optimize antiparasitic treatment protocols. Pharmacogenomics The study of how genes affect a person’s response to drugs. It aims to understand the genetic basis of drug variability and tailor drug therapy to individual patients or animals. Approximately 70% of Phase I and 80% of Phase II drug metabolism is attributed to the CYP450 enzyme system. Knowledge cutoff Cytochrome P450 (CYP) Enzymes A superfamily of enzymes primarily involved in the oxidative metabolism of drugs and other xenobiotics (foreign compounds) within the body. Neonates often have 20-50% reduced CYP enzyme activity compared to adults, requiring dosage adjustments for many drugs. Knowledge cutoff In conclusion, biotransformation is a complex and crucial process in veterinary pharmacology, significantly influencing drug disposition and efficacy. Understanding the pathways involved, the enzymes responsible, and the factors that can affect metabolism is essential for veterinarians to optimize drug therapy, minimize adverse effects, and tailor treatments to individual animal needs. Future research focusing on pharmacogenomics and personalized medicine will further refine our ability to predict and manage drug responses in animals.

Biotransformation of Drugs in Animals | UPSC Mains ANI-HUSB-VETER-SCIENCE-PAPER-II 2019

Biotransformation, also known as drug metabolism, is the process by which the body chemically modifies a drug. It is a critical determinant of drug efficacy, duration of action, and potential toxicity. The process primarily occurs in the liver, but also in other tissues like the kidneys, intestines, and lungs. Understanding biotransformation is fundamental for veterinarians to optimize drug dosage, predict drug interactions, and minimize adverse effects in animals. The complexity arises from the diverse enzymatic reactions involved, which can either activate or inactivate a drug. Recent advances in pharmacogenomics are increasingly revealing individual variations in biotransformation capabilities, impacting treatment outcomes.

Defining Biotransformation

Biotransformation is the enzymatic alteration of a drug within the body. It’s a two-phase process designed to convert lipophilic drugs into more hydrophilic metabolites, facilitating their excretion from the body. Phase I reactions typically involve oxidation, reduction, or hydrolysis, while Phase II reactions involve conjugation, where a polar molecule is added to the drug or its Phase I metabolite.

Phase I Reactions: Functionalization

Phase I reactions introduce or expose a functional group (e.g., -OH, -NH2, -SH) on the drug molecule. This makes the drug more polar, but not always sufficiently so for excretion. The cytochrome P450 (CYP) enzyme system is the most important group of enzymes involved in Phase I.

Oxidation: The most common Phase I reaction, catalyzed by CYP enzymes. Examples include:
- S-oxidation: Metabolism of thioethers.
- N-oxidation: Metabolism of amines.
- Hydroxylation: Addition of -OH groups, common in steroids.
Reduction: Less common than oxidation. Involves the addition of electrons. Important in the metabolism of nitro compounds and some steroids.
Hydrolysis: Involves the addition of water to break ester or amide bonds. Examples include the metabolism of aspirin and procaine.

Phase II Reactions: Conjugation

Phase II reactions involve the conjugation of a drug or its Phase I metabolite with a polar molecule, making it significantly more water-soluble and readily excretable. These reactions are generally catalyzed by transferase enzymes.

Glucuronidation: The most common Phase II reaction. UDP-glucuronosyltransferases (UGTs) catalyze the addition of glucuronic acid to drugs and metabolites.
Sulfation: Sulfotransferases (SULTs) catalyze the addition of sulfate groups.
Acetylation: N-acetyltransferases (NATs) catalyze the addition of acetyl groups.
Glutathione Conjugation: Glutathione S-transferases (GSTs) catalyze the conjugation of glutathione to electrophilic drugs or metabolites. This is an important detoxification pathway.
Amino Acid Conjugation: Conjugation with amino acids like glycine or taurine.

Table: Summary of Biotransformation Pathways

Phase	Reaction Type	Enzymes Involved	Outcome
Phase I	Oxidation	Cytochrome P450 (CYP) enzymes	Introduction or exposure of a functional group
Phase I	Reduction	Various reductases	Addition of electrons
Phase I	Hydrolysis	Esterases, Amidases	Cleavage of ester or amide bonds
Phase II	Glucuronidation	UDP-glucuronosyltransferases (UGTs)	Addition of glucuronic acid
Phase II	Sulfation	Sulfotransferases (SULTs)	Addition of sulfate

Factors Affecting Biotransformation

Several factors can influence the rate and extent of drug biotransformation:

Species Differences: Significant variations exist in enzyme activity and expression across different animal species.
Age: Neonates and geriatric animals often have reduced metabolic capacity.
Disease State: Liver disease significantly impairs biotransformation.
Drug Interactions: Enzyme induction (increased enzyme activity) or inhibition (decreased enzyme activity) by other drugs can alter drug metabolism.
Genetics: Genetic polymorphisms in drug-metabolizing enzymes can lead to variability in drug response.

CYP2D6 Polymorphisms in Dogs The CYP2D6 enzyme is crucial in the metabolism of several drugs in dogs. Genetic variations (polymorphisms) in the CYP2D6 gene can result in "poor metabolizers" (reduced enzyme activity) or "ultra-rapid metabolizers" (increased enzyme activity), significantly impacting drug efficacy and risk of toxicity. This is particularly relevant for drugs like codeine, which is metabolized by CYP2D6 to morphine. What is the difference between enzyme induction and inhibition? Enzyme induction increases the synthesis of metabolizing enzymes (like CYP450s), leading to faster drug metabolism. Enzyme inhibition decreases enzyme activity, slowing down drug metabolism. Veterinary Pharmaceutical Inspection and Enforcement This scheme, overseen by various national regulatory bodies, ensures that pharmaceutical manufacturers adhere to good manufacturing practices (GMP) and quality control standards, indirectly impacting the consistency of drug metabolism studies and ensuring accurate labeling regarding potential drug interactions. Ongoing

Ivermectin Resistance in Parasites Repeated exposure to ivermectin, an antiparasitic drug, has led to the development of resistance in some parasite populations. This resistance often arises due to mutations in parasite genes that alter the drug's target site. However, altered drug metabolism in the host animal (e.g., increased CYP activity leading to faster ivermectin clearance) can also contribute to treatment failure, highlighting the interplay between parasite and host metabolism. Understanding the role of host metabolism in drug resistance is crucial for developing strategies to overcome resistance and optimize antiparasitic treatment protocols.

Pharmacogenomics The study of how genes affect a person’s response to drugs. It aims to understand the genetic basis of drug variability and tailor drug therapy to individual patients or animals. Approximately 70% of Phase I and 80% of Phase II drug metabolism is attributed to the CYP450 enzyme system. Knowledge cutoff Cytochrome P450 (CYP) Enzymes A superfamily of enzymes primarily involved in the oxidative metabolism of drugs and other xenobiotics (foreign compounds) within the body. Neonates often have 20-50% reduced CYP enzyme activity compared to adults, requiring dosage adjustments for many drugs. Knowledge cutoff

Define biotransformation and discuss the pathways of biotransformation of drugs in animal body.

Model Answer

Introduction

Defining Biotransformation

Phase I Reactions: Functionalization

Phase II Reactions: Conjugation

Table: Summary of Biotransformation Pathways

Factors Affecting Biotransformation

Conclusion

Evaluate your handwritten answer in under a minute

Topics Covered